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Abstract
Since the first DNA vaccine studies were done in the 1990s, thousands more studies have followed. Here we report
the development and analysis of DNAVaxDB (http://www.violinet.org/dnavaxdb), the first publically available web-
based DNA vaccine database that curates, stores, and analyzes experimentally verified DNA vaccines, DNA vaccine
plasmid vectors, and protective antigens used in DNA vaccines. All data in DNAVaxDB are annotated from reliable
resources, particularly peer-reviewed articles. Among over 140 DNA vaccine plasmids, some plasmids were more
frequently used in one type of pathogen than others; for example, pCMVi-UB for G- bacterial DNA vaccines, and
pCAGGS for viral DNA vaccines. Presently, over 400 DNA vaccines containing over 370 protective antigens from
over 90 infectious and non-infectious diseases have been curated in DNAVaxDB. While extracellular and bacterial
cell surface proteins and adhesin proteins were frequently used for DNA vaccine development, the majority of
protective antigens used in Chlamydophila DNA vaccines are localized to the inner portion of the cell. The DNA
vaccine priming, other vaccine boosting vaccination regimen has been widely used to induce protection against
infection of different pathogens such as HIV. Parasitic and cancer DNA vaccines were also systematically analyzed.
User-friendly web query and visualization interfaces are available in DNAVaxDB for interactive data search. To
support data exchange, the information of DNA vaccines, plasmids, and protective antigens is stored in the Vaccine
Ontology (VO). DNAVaxDB is targeted to become a timely and vital source of DNA vaccines and related data and
facilitate advanced DNA vaccine research and development.
Background
A DNA vaccine is a bacterial DNA plasmid constructed
to express an encoded protein or peptide antigen(s),
which is administered in vivo and able to induce preven-
tive or therapeutic antigen-specific immune response
against a specific disease or infection. The DNA plasmid
must encode a promoter that is active in mammalian
cells [1]. The first DNA vaccine studies were conducted
in the 1990s, with the first successful experiment done in
1990 when a DNA plasmid expressing a protein was
injected into mice and the protein was successfully
synthesized in vivo [2]. Once expressed, the protective
protein antigen encoded by a gene in a DNA vaccine can
be degraded into peptides by antigen presenting cells.
The protective immune peptides (i.e., epitopes) can then
be transferred to the cell surface and activate T cells. If
the DNA vaccine is taken up by muscle cells, the muscle
cells can transfer the expressed protein to the antigen
presenting cells to stimulate the T cells. DNA vaccines
can also stimulate antibody responses through antigen
recognition by B cells [1]. Compared to other types of
vaccines (e.g., live attenuated or killed whole organism
vaccines, and subunit vaccine), DNA vaccines are safe,
easy to prepare and store, and cost effective. In addition,
DNA vaccines allow for focused immunity on the antigen
of interest and have the ability to induce natural, long-
lasting, and varied immune responses in vivo.
Intensive efforts have been taken to study and use DNA
vaccines. There have been over 55,000 articles indexed in
PubMed and Google Scholar combined. Four DNA vac-
cines have been licensed for veterinary uses. Among
them are two DNA vaccines against infectious diseases,
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including West Nile-Innovator (Fort Dodge Animal
Health, Fort Dodge, IA, USA) for protection against horse
West Nile virus (https://online.zoetis.com/US/EN/Pro-
ducts/Pages/West_Nile_Innovator.aspx), and Apex-IHN
(Novartis Animal Health, Basel, Switzerland) against
infectious haematopoietic necrosis virus in salmon (http://
www.vical.com/products/infectious-disease-vaccines/
Apex-IHN/default.aspx). Oncept (Merial, Lyon, France),
another licensed DNA vaccine, is for protection against
dog melanoma [3]. In addition, one DNA vaccine has
been licensed for a gene therapy application in food pigs
for increasing litter survival of breeding sows: LifeTide SW
5 (VGX Animal Health, Inc. The Woodlands, TX, USA)
(http://www.vgxah.com/LifetideSW5.html). Although
there is not a licensed human DNA vaccine on the market,
many human clinical trials for DNA vaccine evaluation are
currently being conducted. Researchers are continuing to
investigate the mechanisms behind DNA vaccination and
vaccine immunity.
While intensive research has been conducted and
resulted in promising DNA vaccine candidates, there is no
web-based central resource that allows the storage, anno-
tation, comparison, and analysis of experimentally verified
DNA vaccines. VIOLIN (http://www.violinet.org) is the
first web-based comprehensive vaccine database and ana-
lysis system that targets vaccine research [4,5]. Currently,
VIOLIN has included more than 3,200 vaccines for over
180 infectious diseases and many non-infectious diseases
(e.g., cancers and arthritis). Each of the curated vaccines
has been shown to induce significant protection against a
disease in a natural host or at least one laboratory animal
model. Many of the vaccines in VIOLIN are verified DNA
vaccines. However, the general VIOLIN system does not
include any specific information about DNA vaccine plas-
mids. It does not include tools to specifically query and
analyze those protective antigens used in DNA vaccines.
The DNA vaccine-specific plasmids and protective anti-
gens may preserve unique patterns that would support
further DNA vaccine research and development. A specific
query system for DNA vaccines is not available either in
the general system. The DNA vaccine research has
become its own independent research and has its own
community (for example, there is an active DNA Vaccines
LinkedIn group (http://www.linkedin.com/groups/DNA-
Vaccines-3077917)). Therefore, there is a need to develop
a DNA vaccine specific resource.
To address the many needs of the DNA vaccine
community, we have developed DNAVaxDB http://www.
violinet.org/dnavaxdb, a web-based DNA vaccine database
and analysis system. As a relatively independent program
under the umbrella of the VIOLIN vaccine database and
analysis system, DNAVaxDB includes the information for
a large set of DNA vaccines, DNA vaccine plasmids, and
protective antigens used in DNA vaccines. The analysis of
these data reveals many unique patterns specific for DNA
vaccines.
Methods
DNAVaxDB system and database design
DNAVaxDB was developed with a three-tier architecture
built on two HP ProLiant DL380 G6 servers that run the
Redhat Enterprise Linux (release 5.8) operating system. A
query on DNAVaxDB can be submitted from the DNA-
VaxDB web user interface (presentation tier). The query
is then processed using PHP/SQL (middle tier, applica-
tion server based on Apache) against a relational database
(MySQL version 5.5.28) (data tier, database server).
Query results are then displayed in the web browser.
Furthermore, DNAVaxDB curators and reviewers can
submit and review curated vaccine and plasmid data
through the VIOLIN data curation system. Two servers
regularly back up each other’s data. DNAVaxDB is one
relatively independent program under the umbrella of
the VIOLIN vaccine database and analysis system [4].
Figure 1 shows the DNAVaxDB workflow and system
design. For each vaccine, the DNAVaxDB database con-
tains at minimum the following information: (1) General
DNA vaccine information, including name, host animal
used as model, immunization route, vector, antigen
name, stage of vaccine development (e.g. research, clinical
trial, or licensed), and efficacy. Demonstration of protec-
tion through a challenge experiment or a protective level
of antibodies is necessary for inclusion in DNAVaxDB.
This information is manually curated to emphasize the
details of the paper, particularly the protection experi-
ments. Antigens inserted into the vector are searched for
in the NCBI Gene, Protein, and Nucleotide databases.
If found, they are added to VIOLIN by using the Gene,
Protein, or Nucleotide ID and an internal script to
retrieve the information in NCBI, labeled as a “protective
antigen,” and linked to the DNA vaccine in VIOLIN. (2)
DNA vaccine plasmid information. For each plasmid, the
database includes name, Vaccine Ontology ID [6,7], and
reference, and, if available, manufacturer, promoter, anti-
biotics resistance gene, and length. (3) Comprehensive
citation information for each vaccine such as title,
authors, journal, issue, volume, year, and pages. These
references are usually found in PubMed [8], and the
information found in VIOLIN is retrieved from PubMed
using the PubMed ID (i.e., PMID) and an internal script.
Each vaccine and plasmid is assigned a Vaccine Ontology
(VO) identifier, linking the two databases.
Semi-automatic annotation of vaccine information
A semi-automatic DNAVaxDB annotation system is
developed for DNA vaccine and related data curation
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and analysis by modifying an in-house web-based litera-
ture mining and curation system called Limix [4,9,10]
(Figure 2). This system includes two parts: vaccine and
protective antigen data curation based on the existing
VIOLIN curation system [4], and a newly developed
database specifically for DNA vaccine plasmids. The
web-based DNAVaxDB annotation system provides
many interactive features for curators to easily obtain
information. For example, once an NCBI Gene ID is
entered, the system can automatically retrieve all the
gene and protein information (e.g., DNA and protein
sequences, names, functions) from the NCBI Gene data-
base [11] (Figure 2A and 2B). Similarly, a PMID is suffi-
cient for the system to retrieve all reference information.
The curation system also allows a data curator to search
literature, copy and edit text, and submit data to database
(Figure 2C-2E). After a curator submits data, a domain
expert will serve as the data reviewer to review, edit, and
approve the curated data through a user-friendly web
interface. Immediately after the approval by a reviewer,
the curated data submitted will be posted publicly. The
DNAVaxDB annotation also stores all the history
changes and traces the detailed changes made to each
record (Figure 2F).
Analysis of protective antigens used in DNA vaccine
development
For each protective antigen used in DNA vaccine devel-
opment, the Vaxign software program was used for ana-
lysis of subcellular localization and adhesin probability
[12,13]. The analysis of the Clusters of Orthologous
Groups (COG) for each protective antigen was also
performed.
A DNAVaxDB BLAST search program has been devel-
oped to support sequence similarity search on our custo-
mized BLAST library that contains over 370 protective
antigens used in DNA vaccine development.
DNAVaxDB data query, visualization, and analysis
Three user-friendly web interfaces were developed for
users to separately query DNA vaccines, protective anti-
gens, and DNA vaccine plasmids. The three parts of
queries are also interlinked. For example, the display of
the query results of a DNA vaccine will typically include
the plasmid and protective antigen(s) used, and the name
or IDs of these plasmid and antigens can then be linked to
other web pages specifically for the plasmid and antigen.
To perform some systematic bioinformatics analyses,
sometimes we developed MySQL scripts that could
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Figure 1 DNAVaxDB workflow and system design. Data, including vaccine information and evidence from peer-reviewed publications, is
manually curated into DNAVaxDB. Gene IDs, Protein IDs, or Nucleotide IDs are retrieved from NCBI and used by an internal script to gather
detailed information about each protective antigen, which is then stored in DNAVaxDB. DNA and protein sequences can be used for BLAST,
COG, and Vaxign analyses, and the latter two are stored in DNAVaxDB. A PubMed ID (PMID) from the relevant paper is also used by an internal
script to gather comprehensive citation information for each study. Each vaccine and plasmid is assigned a Vaccine Ontology (VO) ID.
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be used to directly interact with the backend MySQL
database. This activity was often performed to quickly cate-
gorize and compare various statistics and characteristics of
the DNA vaccines, plasmids, and antigens.
DNAVaxDB data exchange, transfer, and download
The information of the DNA vaccines, protective anti-
gens, and DNA vaccine plasmids from DNAVaxDB is
stored in Vaccine Ontology (VO; http://www.violinet.
org/vaccineontology) [6]. The VO is developed using the
Web Ontology Language (OWL) that can be automati-
cally processed via software programs [14].
Results
DNAVaxDB statistics
As of September 3, 2013, DNAVaxDB has included 417
DNA vaccines. Each of these DNA vaccines was experi-
mentally verified to be protective or therapeutic with at
least one laboratory animal model. In total, these DNA
vaccines use 141 DNA vaccine plasmids, and 375 pro-
tective antigens have been curated for use in DNA vac-
cines. Occasionally, more than one antigen is used in a
single DNA vaccine. These vaccines are developed
against 99 infectious and non-infectious diseases
(including arthritis, cancer, and diabetes). Table 1 lists
infectious and non-infectious diseases for which DNA-
VaxDB stores 10 or more vaccines. Some protective
antigens are orthologs from different strains. For exam-
ple, Brucella has 15 protective antigens listed. However,
only 10 of them are unique; the other 5 are orthologs of
some of the 10 genes from different Brucella strains.
Analysis of DNAVaxDB vaccine DNA plasmids
The most popular plasmids found in DNAVaxDB were
analyzed (Table 2). Among the most commonly used
plasmids were pcDNA3.1, pcDNA3, pVAX1, pVR1012,
and pCI. Based on the information available on the
manufacturers’ websites, peer-reviewed articles, and
other reliable sources, certain patterns were established
among these popularly used plasmids. The first pattern
found was the common use of the human cytomegalo-
virus/immediate-early (CMV) promoter among almost
all the plasmids. The two popular plasmids that did not
use this promoter, pCAGGS and pCAGGSP7, utilized
Figure 2 Submission and review processes of DNA vaccines into DNAVaxDB. A) The overall view of the top part of the DNAVaxDB data
submission and review page. B) Gene submission form. Once an NCBI Gene, Protein, or Nucleotide ID is entered, an internal script is used to
retrieve information such as Taxonomy ID, protein name, and DNA and protein sequences from NCBI to create a new gene entry in VIOLIN.
C) Vaccine addition page. Information such as vaccine name, plasmid and antigen information, efficacy, and references can be added on this
page. D) Vaccine information section includes all vaccines curated for this pathogen. Any specific vaccine can be further examined and edited.
E) Edit Dialog box. Curators and reviewers can use this tool to edit a specific part of a vaccine (e.g., vaccine name). A reference may also be
added for many items of information (e.g., vaccine efficacy). F) Show Revision History page. Curators and reviewers can use this tool to see
what changes have been made and compare page edits.
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the AG/CMV-IE/lac promoter (http://www.addgene.org/
vector-database/2042/). The CMV promoter elicits
higher expression levels than other promoters, and
therefore is commonly used.
Secondly, several commonly used plasmids utilized an
SV40 polyadenylation terminator. This type of termina-
tor is commonly used to reduce additional peptide
expression or alteration of the expressed peptide [15].
Thirdly, some plasmids have been more frequently
used for development of DNA vaccines against one type
of pathogens than the others (Table 2). For example,
pCAGGS has been used for development of 10 successful
viral DNA vaccines; however, this plasmid has not been
used for any other types of DNA vaccines stored in
DNAVaxDB. Similarly, 10 Gram-negative bacterial DNA
vaccines use the plasmid pCMVi-UB, and this plasmid
has not been used for DNA vaccines against any Gram-
positive bacteria or other types of pathogens (Table 2).
Finally, most of the commonly used plasmids with
information available about antibiotic resistance markers
employed an ampicillin marker. This is a noteworthy
observation, since there is potential hypersensitivity to
ampicillin in some patients, and therefore these plasmids
would not be acceptable for human use. Kanamycin is a
more acceptable marker for human use [15]. Further
research is necessary to determine what makes these plas-
mids so effective in lab animals and what can be done to
modify them for human use, such as replacing the
Table 1 Diseases with 10 or more DNA vaccines in DNAVaxDB
Number of DNA vaccines Number of protective antigens used Number of DNA vaccine plasmids used
G+ bacteria
Bacillus anthracis 15 11 (5)* 10
Mycobacterium tuberculosis 10 8 (8) 7
G- bacteria
Brucella spp. 15 15 (10) 7
Viruses
Dengue virus 13 8 (3) 6
Herpes simplex virus types 1 and 2 19 11 (6) 13
Human immunodeficiency virus 12 34 (10) 10
Influenza virus 46 27 (5) 21
Parasite
Plasmodium spp. 10 12 (8) 9
Trypanosoma cruzi 10 8 (7) 7
Non-infectious disease
Cancer 34 34 (29) 21
*The number inside the parentheses () represents non-ortholog genes
Table 2 Plasmids in DNAVaxDB with five or more associated vaccines
Plasmid VO ID No. of
Vaccines
No. of G-/+ bacterial
vaccines
No. of viral
vaccines
No. of parasitic
vaccines
No. of fungal
vaccines
No. of other
vaccines
pcDNA3.1 VO_0000158 49 15/4 16 7 0 7
pcDNA3 VO_0000132 40 4/1 16 11 0 8
pVAX1 VO_0000024 24 1/2 8 10 0 3
pVR1012 VO_0000334 19 0/4 7 5 1 2
pCI VO_0000212 16 2/4 9 0 0 1
pCI-neo VO_0000214 12 6/1 5 0 0 0
pWRG7077 VO_0000346 11 0/1 9 0 0 1
pJW4303 VO_0000276 10 3/5 1 0 0 1
pCMVi-UB VO_0005027 10 10/0 0 0 0 0
pCAGGS VO_0000099 10 0/0 10 0 0 0
pIRES VO_0000262 9 0/0 9 0 0 0
pCAGGSP7 VO_0005000 8 0/0 8 0 0 0
pVAX VO_0000019 8 0/0 6 0 0 2
pCMV VO_0000215 7 0/0 7 0 0 0
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ampicillin resistance marker with a kanamycin marker and
finding new ways to further increase antigen expression.
Analysis of bacterial DNA vaccines in DNAVaxDB
In total, there are 95 protective bacterial antigens used in
DNA vaccines stored in DNAVaxDB. These protective
antigens are also cross-described in the VIOLIN Protegen
database [16]. It has been reported that most protective
antigens for vaccine development are secreted extracellular
bacterial proteins, cell surface proteins, or adhesins [16].
Therefore, one important aspect of this study is to analyze
these DNA vaccine antigens in terms of their subcellular
localization and adhesin probability and compare these
with the general patterns when all protective antigens for
any types of bacterial vaccines are considered [16].
As shown in Table 3, of the 28 Gram-positive bacterial
protective antigens, 18 (64%) have extracellular localiza-
tion, and 3 (11%) are cell wall proteins. The remaining
antigens are distributed between cytoplasmic region (2 or
7%) and cytoplasmic membrane (5 or 18%). In addition,
11 antigens (39%) are adhesins or adhesin-like proteins.
Therefore, extracellular and adhesin antigens are superior
targets for Gram-positive DNA vaccine construction.
Of the 67 Gram-negative bacterial protective antigens,
the extracellular and outer membrane locations are among
the major subcellular regions with 11 and 20 protective
antigens, respectively (16% and 30%). There are 12 cyto-
plasmic protein antigens (18%). The numbers of cytoplas-
mic membrane and periplasmic proteins are small.
However, there are 18 antigens with unpredicted subcellu-
lar localization. Our study also found that 20 antigens
(30%) used in Gram-negative bacterial DNA vaccines are
adhesin or adhesin-like proteins (Table 3). In summary, we
found that the extracellular or surface or adhesin proteins
preferred targets for Gram-negative DNA vaccine con-
struction; meanwhile, cytoplasmic proteins also form a
group of frequently used antigens in this type of DNA
vaccines.
Although the extracellular, cell surface, and adhesin
proteins are preferred bacterial DNA vaccine antigens, the
data shown in DNA vaccines against Chlamydophila
provides a different view (Table 3 and 4). Fourteen unique
protective Chlamydophila antigens from the Gram-nega-
tive bacterial pathogen were used for development of
experimentally verified DNA vaccines. This species did not
have any antigens that were repeatedly used with different
adjuvants or in different combination with other antigens.
These antigens have many different functions, and in total
there are 7 different COG categories. Among the 14
protective Chlamydophila antigens used, 6 were cytoplas-
mic, 2 were at the cytoplasmic membrane, 3 were at the
outer membrane, 1 was extracellular, and 2 were unknown.
However, the two protective antigens with unknown
localizations are believed to be localized to the cytoplasm;
GatC is part of a larger complex also including GatA and
GatB, which are both localized to the cytoplasm, and Ssb is
a DNA binding protein and DNA is localized to the
cytoplasm. Therefore, different from the common pattern
of high percentage of extracellular and outer membrane
antigens, the majority of protective antigens used for
Chlamydophila DNA vaccines are cytoplasmic proteins.
Analysis of viral DNA vaccines in DNAVaxDB
In total, DNAVaxDB contains over 200 DNA vaccines
against over 40 viruses. In order to get a closer look at
viral DNA vaccines, we chose to analyze human immu-
nodeficiency virus (HIV) and the related diseases simian-
human immunodeficiency virus (SHIV) and simian
immunodeficiency virus (SIV). HIV is a prevalent pro-
blem worldwide. The SHIV and SIV models have been
frequently used for HIV vaccine studies. Information
about the HIV, SHIV, and SIV vaccines can be found in
Table 5. HIV-1 and SHIV89.6P were commonly used
strains for challenge, but there were no strains that were
used the majority of the time. Overall, the HIV, SHIV,
and SIV DNA vaccines found in DNAVaxDB are diverse.
Many aspects of the HIV, SHIV, and SIV DNA vaccines
do not follow any particular pattern. All fourteen of the
vaccines are quite unique and utilize many different tech-
niques in order to obtain protection.
There were many different antigens used, the most com-
mon being env and gag. Env is an envelope protein, which
Table 3 Subcellular localization and adhesin probability of bacterial protective antigens
Gram + bacteria Gram - bacteria Chlamydophila
Total 28 67 14
Extracellular 18 (64%) 11 (16%) 1
Cell wall 3 (11%) N/A N/A
Unknown 0 18 (27%) 2 (15%)
Cytoplasmic 2 (7%) 12 (18%) 6 (46%)
Cytoplasmic Membrane 5 (18%) 2 (3%) 2 (15%)
Periplasmic N/A 4 (6%) 0
Outer Membrane N/A 20 (30%) 3 (23%)
Average Adhesin Probability (# antigens with > 0.51) 0.43 (11, 39%) 0.40 (20, 30%) 0.26 (0)
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Table 4 Antigens in DNAVaxDB for Chlamydophila spp.
Antigen Protein ID Species Localization (probability) COG PMID
CAB049 62184696 C. abortus Cytoplasmic membrane (1) Cell wall/membrane biogenesis 15811648
CAB613 62185225 C. abortus Cytoplasmic (0.997) Amino acid transport and metabolism 15811648
DnaK 26006347 C. abortus Cytoplasmic (0.997) N/A 12056482
DnaX 62148024 C. abortus Cytoplasmic (0.997) N/A 15811648
GatA 62184918 C. abortus Cytoplasmic (0.997) Translation, ribosomal structure and biogenesis 15811648
GatB 62147986 C. abortus Cytoplasmic (0.896) N/A 15811648
GatC 62184917 C. abortus Unknown (0.2) Translation, ribosomal structure and biogenesis 15811648
OmlA 62184824 C. abortus Outer membrane (1) N/A 15811648
Pomp90A 187438939 C. abortus Extracellular (0.946) N/A 15811648
Omp1 40601 C. abortus Outer membrane (1) N/A 15811648
FabD 15618217 C. pneumoniae Cytoplasmic (0.926) Lipid transport and metabolism 16434129
PknD 161353778 C. pneumoniae Cytoplasmic (0.788) Signal transduction; transcription; replication, recombination, and
repair
16434129
Ssb 15618301 C. pneumoniae Unknown (0.2) Replication, recombination, and repair 16434129
OmpA 94467392 C. psittaci Outer membrane (0.992) N/A 20199760
Table 5 HIV, SHIV, and SIV DNA vaccines
# DNA Vaccine Antigen name(s) Challenge:
HIV/SHIV
strain
DNA
plasmid
Vaccination regimen PMID
(year)
DNA vaccine alone
1 HIV DNA vaccine VlJns-tPA-gp120 gp120 HIV-1 VlJns DNA vaccine alone 9127013
(1997)
2 HIV-2 DNA vaccine gag, nef, tat, env HIV-2UC2/9429 pND-14 DNA vaccine with GM-CSF
and B7-2 adjuvants
15149785
(2004)
3 SIV DNA vaccine encoding SIV core protein Core protein SHIV89.6P pCSIVgag DNA vaccine with IL-15
adjuvant
18000037
(2007)
4 DNA vaccine expressing multiple HIV epitopes rev, nef, tat, gag,
env, pol
HIV-1 Auxo-GTU
vector
system
DNA vaccine alone 16359234
(2005)
5 HIV DNA vaccine pHIS-SHIV-B env, gag, pol, tat,
rev, vpu
SHIV(mn229) pHIS-64 DNA vaccine alone 15564490
(2004)
6 HIV DNA vaccine pCMN160 env, rev, gag-pol HIV-1 SF2 pCMN160 DNA vaccine alone 9142121
(1997)
DNA vaccine priming and other vaccine boosting
7 HIV DNA vaccine SIVmac239 Gag-Pol-Nef and
mock Env with rAd5 boost
gag, pol, nef, env SHIV89.6P pVR1012 DNA vaccine prime,
adenovirus boost
15613305
(2005)
8 HIV DNA and adenoviral vector Ad5 expressing
SIV gag protein
gag SHIV 89.6P16 pV1R DNA prime, adenovirus
boost
11797011
(2002)
9 HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) gag, pol, env, tat,
rev, vif, vpr, vpu
SHIV-89.6P pGA DNA vaccine with GM-CSF
adjuvant prime, MVA boost
16740288
(2006)
10 DNA and poxvirus priming-boosting SHIV vaccine env, gag SHIV-89.6P pV1R DNA prime with IL-2/Ig
adjuvant, poxvirus boost
15258286
(2004)
11 HIV priming with DNA vaccine expressing HIV
gp160 protein and boosted with Ad5/35 vector
env, rev HIV-1 pCAGGS DNA prime, adenovirus
boost
16079886
(2005)
12 SHIV DNA vaccine encoding env and gag env (4 from 3
clades*), gag
SHIV-Ba-L pSW3891 DNA vaccine prime, protein
boost
16460776
(2006)
13 SHIV(Ba-L) DNA vaccine encoding env and gag env (5 from 4
clades), gag
SHIV-Ba-L pSW3891 DNA vaccine prime, protein
boost
16128917
(2005)
14 SIV DNA vaccine pVacc4 encoding env from
mac239
env SHIV89.6P pVacc4 DNA vaccine with IL-2/Ig
adjuvant prime, MVA boost
15004179
(2004)
*The polyvalent DNA vaccines encoded four env genes from four four primary HIV-1 isolates in three clades: 92US715.6 (clade B), Ba-L (clade B), 96ZM651 (clade
C), and 93TH976.17 (clade E).
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is synthesized as gp160 and later cleaved into gp120 and
gp41 [17]. Gag functions in the construction of virus-like
particles (VLPs) [18]. Frequently more than one antigen
has been used for HIV vaccine development (Table 5).
Only two plasmids were repeatedly used for at least
two vaccines: pV1R and pSW3891. Although pcDNA3.1
is the most common DNA vaccine plasmid used in
DNA vaccine development according to the statistics in
DNAVaxDB (Table 2), this plasmid is not frequently
used in HIV vaccine development. A few studies used
pcDNA3.1 for HIV vaccine development, but protection
was not evaluated in these investigations. For example,
Du and colleagues built two vaccines, pcDNA-Vif and
pcDNA-LIGHT, both based on pcDNA3.1. They then
measured antibodies and T-cell responses [19]. How-
ever, since a protection study was not done, we could
not include this paper in DNAVaxDB.
One pattern that did stand out was the division between
prime-boost vaccines that employed the DNA vaccine as a
prime and DNA vaccination alone. Eight of the vaccines in
DNAVaxDB are prime-boost vaccines, and six are DNA
vaccines alone. Five out of the 14 HIV DNA vaccines are
also mixed with adjuvants to boost host immune responses.
After analysis of the two groups, it was discovered that
most of the prime-boost vaccines demonstrated high or
complete protection of all challenged animals. Looking at
the dates of each study, it’s also clear that the prime-boost
studies were more recent while the older studies were
usually DNA vaccination alone.
Analysis of parasite DNA vaccines in DNAVaxDB
DNAVaxDB contains 61 DNA vaccines against 16 pro-
tozoan pathogens. The two pathogens with the most
vaccines were Plasmodium spp. and Toxoplasma gondii,
as seen in Table 1. These two pathogens also had the
most protective antigens out of all parasites. Analysis of
Plasmodium vaccines showed a wide range of vaccina-
tion methods. Variety was seen most commonly in
immunization route (i.e. gene gun, intramuscular, etc.)
and vaccination regimen (i.e. with or without an adju-
vant, with or without boosting). However, as with all
vaccines in DNAVaxDB, all these different methods
proved efficacious and provided protection, demonstrat-
ing that there are multiple ways to stimulate a host’s
immune response via DNA vaccine.
Analysis of cancer DNA vaccines in DNAVaxDB
Cancer vaccines found in DNAVaxDB were analyzed, as
cancer is the major non-infectious disease found in the
database. Of the 34 cancer protective antigens, 8 were
localized to the cytoplasmic membrane, 3 to the cyto-
plasm, 1 to the outer membrane, 2 are extracellular, and
20 have an unknown location. Eliminating those with an
unknown location, 11 of the 14 protective antigens have
locations near or on the outside of the cell. This makes for
easier access for antibodies. Another noteworthy observa-
tion is that nearly all the vaccines stored in DNAVaxDB
are used for the prevention of tumors rather than the
treatment of existing tumors. While cancer prevention is
important, treatment is more clinically significant [20].
DNA vaccines for cancer treatment need to be able to eli-
cit a tumor-specific response to kill tumor cells and con-
trol the growth of new cells. The vaccines that have been
discovered for cancer treatment thus far are effective using
experimental models. However, in most cases, clinical
trials are needed to evaluate the possibilities of using these
DNA vaccines to confer protective immunity in humans.
DNAVaxDB data query, display, and data sharing
All information stored in DNAVaxDB is publically avail-
able for download and exchange as described in the Mate-
rials and Methods section. The curated DNAVaxDB data
can be proficiently queried by vaccine, plasmid, or protec-
tive antigen as seen in Figure 3.
The Vaccine Ontology (VO) is a community-based
ontology that represents the vaccines and vaccine-related
terms and the relations among these terms [7,21]. VO is
developed using the machine-processable Web Ontology
Language (OWL) format [22]. All the DNA vaccines,
DNA vaccine plasmids, and protective antigens used in
these DNA vaccines, and the relations among these
terms, have been logically represented in VO. The inclu-
sion of these data in VO allows software programs to
easily process the data and use them for further applica-
tion. In addition, the vaccine information in the Vaccine
Ontology (VO) has also been used to integrate the data
in the DNAVaxDB web project design. For example, the
VO information is queried using internal SPARQL [23]
scripts against a Resource Description Framework (RDF)
triple store [24] that stores the ontology contents. The
VO IDs of different vaccines are used as the glue that
links the vaccines in the DNAVaxDB database and the
general VIOLIN vaccine database.
Discussion
To the best of our knowledge, DNAVaxDB is the first
web-based, publically available database and analysis sys-
tem that targets the curation and analysis of DNA vac-
cines, related DNA vaccine plasmids, and protective
antigens. DNAVaxDB contains manually-curated DNA
vaccines that have been used in the prevention and
treatment of a wide variety of infectious diseases, as well
as diseases such as cancer. Analysis of DNAVaxDB data
has allowed us to reveal specific patterns from the
experimentally verified DNA vaccines, plasmids, and
protective antigens. These results support better under-
standing of protective DNA vaccine mechanisms and
facilitate rational DNA vaccine design.
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A few challenges have been identified throughout the
DNA vaccine curation process. One challenge is that
many DNA vaccines have been developed, but very few
offer significant protection against challenge. Finding
vaccines that offered robust protection in animal models
could be difficult at times. To make DNAVaxDB valu-
able, we insisted that all DNA vaccines stored in the
database were experimentally verified to induce protec-
tion in at least one laboratory animal model. Accuracy
will not only provide more precise analysis, but also
make DNAVaxDB a more useful tool for researchers.
In most cases, our studies with protective antigens col-
lected in DNAVaxDB are consistent with previous finding
that the bacterial surface or extracellular proteins are often
good vaccine candidates [10,16]. We have previously iden-
tified another group of microbial genes called “virmugens”,
which is coined to represent a gene that encodes for a
pathogen virulence factor and has been proven feasible in
at least one animal model to make a live attenuated vac-
cine after this gene is knocked out [25]. It has been known
that virulence or pathogenic factors can often be used as
protective antigens [26]. Our study also found that some
virmugens, such as herpes simplex virus 1 gD [27,28],
Brucella melitensis Omp25 [29,30], and influenza virus
M2 [31,32], are used for DNA vaccine development and
function as protective antigens. More specific studies
should be performed to investigate the relationships
among general protective antigens, protective antigens
used in DNA vaccine development, and virmugens.
Although many bacterial DNA vaccines use surface or
extracellular proteins as protective antigens, surprisingly
almost the half of the Chlamydophila protective antigens
used in DNA vaccines are cytoplasmic, Cytoplasmic inner
proteins are typically not accessible to antibodies. It sug-
gests that other immune response mechanism(s), such as
cytolytic T lymphocytes (CTL) reactivity inducible by both
Figure 3 An example of searching a vaccine and its related information in DNAVaxDB. (A) The vaccine name “mic8” is queried in DNAVaxDB.
(B) The resulting vaccine in DNAVaxDB. (C) The DNAVaxDB page obtained by clicking on “T gondii DNA vaccine encoding MIC8” in (B). The DNAVaxDB
page for the vaccine has information about the vaccine (protective antigen inserted, vector, host response, etc.). (D) The gene information page
obtained by clicking on the “Detailed Gene Information Here” link from (C). This gives more information about the protective antigen used in the
vaccine. (E) The Ontobee [40] page detailing the hierarchy of VO and showing the place of pVAX1, the plasmid used in this vaccine. This page is
obtained by clicking on the VO ID in (C). The plasmid name can also be clicked to access a plasmid-specific page (data not shown).
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inner and outer proteins, are most likely responding to
these antigens [1]. However, antibodies are an important
immune response, and the inability to generate such an
antibody response would seem to be detrimental to a vac-
cine. Several of these candidates came from one paper,
who also discovered that the outer membrane proteins are
not always protective either [33]. More work needs to be
done on this pathogen as well as other pathogens to better
understand the protective vaccine mechanisms associated
with different types of antigens.
As demonstrated in the patterns identified from the HIV,
SHIV, and SIV DNA vaccine research, the prime-boost
vaccination with DNA priming has been of particular inter-
est recently due to its effectiveness. This vaccination regi-
men is able to elicit a T cell response that is focused on the
antigens encoded in the vaccine. This allows for a focused
and potent immune response [34]. The prime-boost
method is also cost-effective; DNA vaccines alone are fairly
inexpensive to manufacture. However, DNA vaccines must
be administered in high doses to be effective alone, which
negates their cost effectiveness advantage. By using a DNA
vaccine as a priming vaccine, which can be administered in
much smaller quantities than if the DNA vaccine was used
alone, it will result in a cost advantage. Further, some
boosting vaccines, such as protein vaccines, can be expen-
sive, so by using DNA vaccines as a priming vaccine
instead of a protein vaccine as both a priming and a boost-
ing vaccine, it provides further savings [35]. Prime-boost
vaccines in DNAVaxDB also used a variety of vaccines for
the boost. Three of the eight HIV DNA vaccines utilized
adenovirus vectors (Table 5). These vectors are popular
due to their ability to elicit strong T cell responses, and
several different serotypes of adenoviruses have been
explored as potential vectors. However, several other vec-
tors, such as poxviruses and modified vaccinia virus Ankara
(MVA), have been used to generate recombinant vector
vaccines for boosting, and the administration of protein
boost vaccines has also been frequently used for boosting
host B cell immune responses [34,36-39]. The frequent use
of the prime-boost regimen strategy is evident in DNA-
VaxDB, as the database contains many prime-boost DNA
vaccines with different types of vaccines for boosting.
The DNAVaxDB database and analysis system has many
applications, with one being the ability to support rational
vaccine design. Since DNAVaxDB stores both plasmids
and protective antigens used in DNA vaccines, this infor-
mation can be used to mix and match the components to
create the safest and most efficacious vaccines possible.
Further, DNA vaccines can be designed based on success-
ful plasmid and protective antigen combinations in other
pathogens. We plan to develop new software capabilities
in the future to support rational DNA vaccine design.
DNAVaxDB is slated to become a vital source of DNA
vaccine information and will support researchers in the
areas of immunology, vaccinology, and microbiology. As
a central and vital source of DNA vaccines, DNAVaxDB
is a timely repository and is expected to have a signifi-
cant impact for vaccine research and development.
List of abbreviations
CMV: Cytomegalovirus; COG: Clusters of Orthologous Groups; CTL: Cytotoxic
T lymphocyte; DNA: Deoxyribonucleic acid; HIV: Human immunodeficiency
virus; MVA: Modified vaccinia virus Ankara; NCBI: National Center for
Biotechnology Information; PMID: PubMed identification number; RDF:
Resource Description Framework; SIV: Simian immunodeficiency virus; SHIV:
Simian-human immunodeficiency virus; OWL: Web Ontology Language;
VIOLIN: Vaccine Investigation and Online Information Network; VO: Vaccine
Ontology
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RR: Data curation and review, data analysis, and manuscript writing. XL, MP:
Data curation. ZX: Data processing, software programming, and database
administrator. YH: Project design, result analysis and interpretation, and
manuscript writing. All authors approved the paper publication.
Declaration statement
The publication funding came from NIH-NIAID grant R01AI081062.
This article has been published as part of BMC Bioinformatics Volume 15
Supplement 4, 2014: Selected articles on Computational Vaccinology 2013.
The full contents of the supplement are available online at http://www.
biomedcentral.com/bmcbioinformatics/supplements/15/S4.
Authors’ details
1Unit for Laboratory Animal Medicine, University of Michigan Medical School,
Ann Arbor, MI 48109, USA. 2College of Pharmacy, University of Michigan,
Ann Arbor, MI 48109, USA. 3College of Literature, Science, and the Arts,
University of Michigan, Ann Arbor, MI 48109, USA. 4Department of
Microbiology and Immunology, University of Michigan Medical School, Ann
Arbor, MI 48109, USA. 5Center for Computational Medicine and Biology,
University of Michigan, Ann Arbor, MI 48109, USA. 6Comprehensive Cancer
Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Published: 19 March 2014
References
1. Liu MA: DNA vaccines: a review. Journal of internal medicine 2003,
253(4):402-410.
2. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL:
Direct gene transfer into mouse muscle in vivo. Science 1990,
247(4949 Pt 1):1465-1468.
3. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM,
Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P,
Houghton AN, Perales MA, Wolchok JD: Development of a xenogeneic
DNA vaccine program for canine malignant melanoma at the Animal
Medical Center. Vaccine 2006, 24(21):4582-4585.
4. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y,
Olenzek EA, Zhao B, Colby LA, Rush HG, Gilsdorf JR, Jourdian GW, He Y:
VIOLIN: vaccine investigation and online information network. Nucleic
Acids Res 2008, 36(Database):D923-928.
5. He Y, Racz R, Sayers S, Lin Y, Todd TE, Hur J, Li X, Patel M, Zhao B,
Chung M, Ostrow J, Sylora A, Dungarani P, Ulysse G, Kochhar K, Bidri B,
Strait K, Jourdian GW, Xiang Z: Updates on the Web-based VIOLIN
Vaccine Database and Analysis System. Nucl Acids Res 2014, 42(1):
D1124-D1132.
6. He Y, Cowell L, Diehl AD, Mobley HL, Peters B, Ruttenberg A,
Scheuermann RH, Brinkman RR, Courtot M, Mungall C, Xiang Z, Chen F,
Todd T, Colby LA, Rush H, Whetzel T, Musen MA, Athey BD, Omenn GS,
Smith B: VO: Vaccine Ontology. The 1st International Conference on
Biomedical Ontology (ICBO-2009) Buffalo, NY, USA; 2009, Nature
Precedings; 2009: http://precedings.nature.com/documents/3552/
version/1.
Racz et al. BMC Bioinformatics 2014, 15(Suppl 4):S2
http://www.biomedcentral.com/1471-2105/15/S4/S2
Page 10 of 11
7. Lin Y, He Y: Ontology representation and analysis of vaccine formulation
and administration and their effects on vaccine immune responses.
J Biomed Semantics 2012, 3(1):17.
8. The US National Library of Medicine. , The PubMed database: http://www.
ncbi.nlm.nih.gov/pubmed/, accessed on September 5, 2013.
9. Xiang Z, Zheng W, He Y: BBP: Brucella genome annotation with literature
mining and curation. BMC Bioinformatics 2006, 7(1):347.
10. Yang B, Sayers S, Xiang Z, He Y: Protegen: a web-based protective
antigen database and analysis system. Nucleic Acids Res 2011,
39(Database):D1073-1078.
11. Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: gene-centered
information at NCBI. Nucleic Acids Res 2011, 39(Database):D52-57.
12. Xiang Z, He Y: Genome-wide prediction of vaccine targets for human
herpes simplex viruses using Vaxign reverse vaccinology. BMC
Bioinformatics 2013, 14(Suppl 4):S2.
13. He Y, Xiang Z, Mobley HL: Vaxign: the first web-based vaccine design
program for reverse vaccinology and applications for vaccine
development. J Biomed Biotechnol 2010, 2010:297505.
14. Xiang Z, Courtot M, Brinkman RR, Ruttenberg A, He Y: OntoFox: web-based
support for ontology reuse. BMC Res Notes 2010, 3:175.
15. Williams JA, Carnes AE, Hodgson CP: Plasmid DNA vaccine vector design:
impact on efficacy, safety and upstream production. Biotechnology
advances 2009, 27(4):353-370.
16. He Y, Xiang Z: Bioinformatics analysis of bacterial protective antigens in
manually curated Protegen database. Procedia in Vaccinology 2012, 6:3-9.
17. Checkley MA, Luttge BG, Freed EO: HIV-1 envelope glycoprotein
biosynthesis, trafficking, and incorporation. J Mol Biol 2011, 410(4):582-608.
18. Freed EO: HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology 1998, 251(1):1-15.
19. Du J, Wu X, Long F, Wen J, Hao W, Chen R, Kong X, Qian M, Jiang W:
Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT
gene adjuvant. Viral immunology 2013, 26(1):68-74.
20. Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, Chiba T, Tanaka K, Li Y,
Furue M, Chou B, Imai T, Duan X, Himeno K: A novel DNA vaccine based
on ubiquitin-proteasome pathway targeting ‘self’-antigens expressed in
melanoma/melanocyte. Gene therapy 2005, 12(13):1049-1057.
21. Ozgur A, Xiang Z, Radev DR, He Y: Mining of vaccine-associated IFN-
gamma gene interaction networks using the Vaccine Ontology. J Biomed
Semantics 2011, 2(Suppl 2):S8.
22. W3C: OWL 2 Web Ontology Language Quick Reference Guide (Second
Edition), W3C Recommendation 11 December 2012. 2012 [http://www.
w3.org/TR/owl2-quick-reference/].
23. SPARQL query language for RDF. [http://www.w3.org/TR/rdf-sparql-query/].
24. Beckett D: The W3C Consortium. RDF/XML syntax specification. 2004
[http://www.w3.org/TR/rdf-syntax-grammar/], accessed on September 5, 2013.
25. Racz R, Chung M, Xiang Z, He Y: Systematic annotation and analysis of
“virmugens” - virulence factors whose mutants can be used as live
attenuated vaccines. Vaccine 2013, 31(5):797-805.
26. He Y, Rappuoli R, De Groot AS, Chen RT: Emerging vaccine informatics.
J Biomed Biotechnol 2010, 2010:218590.
27. Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM: An HSV-1
gD mutant virus as an entry-impaired live virus vaccine. Vaccine 2008,
26(9):1195-1203.
28. Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N: An ocular mucosal
administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21
confers protection against mucosal challenge with herpes simplex virus
type 1 in mice. Vaccine 2011, 29(7):1455-1462.
29. Edmonds MD, Cloeckaert A, Elzer PH: Brucella species lacking the major
outer membrane protein Omp25 are attenuated in mice and protect
against Brucella melitensis and Brucella ovis. Vet Microbiol 2002, 88(3):205-221.
30. Commander NJ, Spencer SA, Wren BW, MacMillan AP: The identification
of two protective DNA vaccines from a panel of five plasmid
constructs encoding Brucella melitensis 16M genes. Vaccine 2007,
25(1):43-54.
31. Watanabe S, Watanabe T, Kawaoka Y: Influenza A virus lacking M2 protein
as a live attenuated vaccine. J Virol 2009, 83(11):5947-5950.
32. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z,
Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and
protection against influenza viruses, including subtype H5N1. Emerg
Infect Dis 2007, 13(3):426-435.
33. Stemke-Hale K, Kaltenboeck B, DeGraves FJ, Sykes KF, Huang J, Bu CH,
Johnston SA: Screening the whole genome of a pathogen in vivo for
individual protective antigens. Vaccine 2005, 23(23):3016-3025.
34. Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB: Selected
approaches for increasing HIV DNA vaccine immunogenicity in vivo.
Curr Opin Virol 2011, 1(4):233-240.
35. Lu S: Immunogenicity of DNA vaccines in humans: it takes two to tango.
Human vaccines 2008, 4(6):449-452.
36. Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A,
Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ: Prime-boost vectored
malaria vaccines: progress and prospects. Human vaccines 2010, 6(1):78-83.
37. Robert-Guroff M: Replicating and non-replicating viral vectors for vaccine
development. Current opinion in biotechnology 2007, 18(6):546-556.
38. McShane H, Hill A: Prime-boost immunisation strategies for tuberculosis.
Microbes Infect 2005, 7(5-6):962-967.
39. Prud’homme GJ: DNA vaccination against tumors. The journal of gene
medicine 2005, 7(1):3-17.
40. Xiang Z, Mungall C, Ruttenberg A, He Y: Ontobee: A linked data server
and browser for ontology terms. The 2nd International Conference on
Biomedical Ontologies (ICBO): 2011 2013, CEUR Workshop Proceedings;
279-281[http://ceur-ws.org/Vol-833/paper48.pdf].
doi:10.1186/1471-2105-15-S4-S2
Cite this article as: Racz et al.: DNAVaxDB: the first web-based DNA
vaccine database and its data analysis. BMC Bioinformatics 2014
15(Suppl 4):S2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Racz et al. BMC Bioinformatics 2014, 15(Suppl 4):S2
http://www.biomedcentral.com/1471-2105/15/S4/S2
Page 11 of 11
